A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Status:
Completed
Trial end date:
2019-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter,open, prospective and single arm study is to evaluate the
efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed
CML-CP.